
                                SEQUENCE LISTING

<110>THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY
     Gerhard MULTHAUP

<120> USE OF AB34 TO ASSESS ALZHEIMER'S
  DISEASE PROGRESSION

<130> 05001770-842PCT

<150> US 62/829,284       
<151> 2019-04-04 

<160> 5

<170> FastSEQ for Windows Version 4.0

<210> 1
<211> 366
<212> DNA
<213> Artificial Sequence

<220> 
<223> heavy chain variable region sequence of AB34
      antibody

<400> 1
gtgaagctgg tggagtctgg gggaggctta gtgaagcctg gagggtccct gaaactctcc 60
tgtgcagcct ctggattcac tttcagtacc tatgccatgt cttgggttcg ccagactcca 120
gagaagaggc tggagtgggt cgcatccatt agtagtggtg gtaacaccta ctatccagac 180
agtgtgaagg gccgattcac catctccaga gataatgcca ggcacatcct gtacctgcaa 240
atgagcagtc tgaggtctga ggacacggcc atgtattact gtgcaagaga ttcttattac 300
ttcggtaata gcgtttacta tgctatggac tactggggtc aaggaacctc agtcaccgtc 360
tcctca                                                            366

<210> 2
<211> 122
<212> PRT
<213> Artificial Sequence

<220> 
<223> heavy chain variable region sequence of AB34
      antibody

<400> 2
Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser
 1               5                  10                  15      
Leu Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr Tyr Ala
            20                  25                  30          
Met Ser Trp Val Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val Ala
        35                  40                  45              
Ser Ile Ser Ser Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys Gly
    50                  55                  60                  
Arg Phe Thr Ile Ser Arg Asp Asn Ala Arg His Ile Leu Tyr Leu Gln
65                  70                  75                  80  
Met Ser Ser Leu Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg
                85                  90                  95      
Asp Ser Tyr Tyr Phe Gly Asn Ser Val Tyr Tyr Ala Met Asp Tyr Trp
            100                 105                 110         
Gly Gln Gly Thr Ser Val Thr Val Ser Ser
        115                 120         


<210> 3
<211> 339
<212> DNA
<213> Artificial Sequence

<220> 
<223> light chain variable region sequence of AB34
      antibody

<400> 3
gatgttgtga tgacccagac tccattcatt ttgtcggtga ccatcggaca accagcctcc 60
atctcttgca agtcaagtca gagcctctta gatagtgatg gaaaaacata tttgaattgg 120
ttgtttcaga ggccaggcca gtccccaaag cggctaatct atcaggtgtc taaagtggac 180
gctggagtcc ctgacaggtt ctctggcagt ggatcaggga cagatttcac actgaaaatc 240
agcagagtgg aggctgagga tttgggaatt tattattgct ggcaaggtac acattttcct 300
cggacgttcg gtggaggcac caaactggaa atcaaacgg                        339

<210> 4
<211> 113
<212> PRT
<213> Aritificial sequence

<220> 
<223> light chain variable region sequence of AB34
      antibody

<400> 4
Asp Val Val Met Thr Gln Thr Pro Phe Ile Leu Ser Val Thr Ile Gly
 1               5                  10                  15      
Gln Pro Ala Ser Ile Ser Cys Lys Ser Ser Gln Ser Leu Leu Asp Ser
            20                  25                  30          
Asp Gly Lys Thr Tyr Leu Asn Trp Leu Phe Gln Arg Pro Gly Gln Ser
        35                  40                  45              
Pro Lys Arg Leu Ile Tyr Gln Val Ser Lys Val Asp Ala Gly Val Pro
    50                  55                  60                  
Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile
65                  70                  75                  80  
Ser Arg Val Glu Ala Glu Asp Leu Gly Ile Tyr Tyr Cys Trp Gln Gly
                85                  90                  95      
Thr His Phe Pro Arg Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys
            100                 105                 110         
Arg
    


<210> 5
<211> 34
<212> PRT
<213> Human

<220> 
<223> Human AB34 sequence

<400> 5
Asp Ala Glu Phe Arg His Asp Ser Gly Tyr Glu Val His His Gln Lys
 1               5                  10                  15      
Leu Val Phe Phe Ala Glu Asp Val Gly Ser Asn Lys Gly Ala Ile Ile
            20                  25                  30          
Gly Leu
        

